Two recent studies have raised concern that the use of ipratropium and tiotropium for COPD is associated with an increased risk of cardiovascular events. However a large four-year study did not detect any increase in risk. Tiotropium remains a safe and effective treatment for most patients with COPD.
In this article
View / Download pdf
version of this article
Anticholinergics and cardiovascular safety
Two recent studies have raised concerns that the use of the anticholinergics ipratropium and tiotropium for COPD is
associated with an increased risk of cardiovascular events. However, a large randomised controlled trial conducted over
four years did not show an increase in cardiovascular risk when tiotropium was compared with placebo. The consensus is
that tiotropium remains a safe and effective treatment for most patients with COPD.
- Todd A et al. Risk of death associated with medications for recently diagnosed chronic obstructive pulmonary disease.
Ann Intern Med 2008; 149:380-90
- Sonal S et al. Inhaled anticholinergics and risks of major adverse cardiovascular events in patients with chronic
obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 2008; 300(12):1439-50
- Tashkin DP et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
- Most COPD patients OK on inhaler. New Zealand Doctor. 22 October 2008:17